EP
RLAY icon

Essential Partners’s Relay Therapeutics RLAY Stock Holding History

Essential Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.9K Sell
2,026
-3,332
-62% -$48.4K 0.02% 683
2026
Q1 		$53.3K Buy
5,358
+12
+0.2% +$107 0.02% 586
2025
Q4 		$45.2K Hold
5,346
– – 0.01% 637
2025
Q3 		$27.9K Buy
5,346
+186
+4% +$709 0.01% 787
2025
Q2 		$17.9K Buy
+5,160
New +$15.3K 0.01% 704

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Essential Partners's RLAY Position: Q2 2026 in Review

Essential Partners reduced its Relay Therapeutics (RLAY) stake by 62% in Q2 2026, selling an estimated $48.4K and leaving 2,026 shares worth $37.9K. The position accounts for 0.02% of the portfolio, ranked #683.

Essential Partners first reported a position in RLAY in Q2 2025 and has held it in 5 quarters since. The position peaked at $53.3K in Q1 2026. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Essential Partners held 2,026 shares of Relay Therapeutics worth $37.9K as of Q2 2026.
  • Essential Partners sold 3,332 Relay Therapeutics shares in Q2 2026, an estimated $48.4K.
  • Relay Therapeutics made up 0.02% of Essential Partners's portfolio in Q2 2026, its #683 holding.
  • Essential Partners first reported a position in Relay Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Relay Therapeutics position peaked at $53.3K in Q1 2026.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.